Prognostic DNA methylation markers for prostate cancer

International Journal of Molecular Sciences

Volumn 15, Issue 9, 2014, Pages 16544-16576

  Strand, Siri H ^a   Orntoft, Torben F ^a   Sorensen, Karina D ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Biomarker; DNA methylation; Epigenetics; Prognosis; Prostate cancer

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR GAMMA2; ALDEHYDE OXIDASE; APC PROTEIN; COILED COIL DOMAIN CONTAINING 181; CYCLOOXYGENASE 2; EPOXIDE HYDROLASE; GLUTATHIONE TRANSFERASE; HYALURONAN AND PROTEOGLYCAN LINK PROTEIN 3; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR PITX2; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CCDC181 PROTEIN, HUMAN; DNA; MICRORNA; MIRN224 MICRORNA, HUMAN; MIRN452 MICRORNA, HUMAN; PROTEIN; RNA; TUMOR PROTEIN;

ANDROGEN DEPRIVATION THERAPY; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER PROGNOSIS; CANCER STAGING; CELL ADHESION; CELL PROLIFERATION; CHROMOSOME 3; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; GLEASON SCORE; HOMEOBOX; HUMAN; NEEDLE BIOPSY; POLYMERASE CHAIN REACTION; PROSTATE CANCER; REVIEW; TRANSURETHRAL RESECTION; TUMOR GROWTH; TUMOR RECURRENCE; ADENOCARCINOMA; BODY FLUID; CHEMISTRY; EARLY DIAGNOSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; MALE; MORTALITY; PHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROMOTER REGION; PROSTATE TUMOR; TUMOR INVASION;

ADENOCARCINOMA; BIOLOGICAL MARKERS; BODY FLUIDS; DNA METHYLATION; DNA, NEOPLASM; EARLY DETECTION OF CANCER; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; PROTEINS; RNA, NEOPLASM;

EID: 84907863142     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms150916544     Document Type: Review

References (114)

1. Crawford, E. D. Epidemiology of prostate cancer. Urology 2003, 62, 3-12.
2. SEER Stat Fact Sheets: Prostate Cancer; Avaible online: http://seer. cancer. gov/statfacts/html/prost. html (accessed on 6 June 2014).
3. Albertsen, P. C.; Hanley, J. A.; Fine, J. 20-year outcomes following conservative management of clinically localized prostate cancer. J. Am. Med. Assoc. 2005, 293, 2095-2101.
4. Roehl, K. A.; Han, M.; Ramos, C. G.; Antenor, J. A.; Catalona, W. J. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3478 consecutive patients: Long-term results. J. Urol. 2004, 172, 910-914.
5. Steineck, G.; Helgesen, F.; Adolfsson, J.; Dickman, P. W.; Johansson, J. E.; Norlen, B. J.; Holmberg, L.; Scandinavian Prostatic Cancer Group Study, N. Quality of life after radical prostatectomy or watchful waiting. N. Engl. J. Med. 2002, 347, 790-796.
6. Kattan, M. W.; Eastham, J. A.; Wheeler, T. M.; Maru, N.; Scardino, P. T.; Erbersdobler, A.; Graefen, M.; Huland, H.; Koh, H.; Shariat, S.; et al. Counseling men with prostate cancer: A nomogram for predicting the presence of small, moderately differentiated, confined tumors. J. Urol. 2003, 170, 1792-1797.
7. Steyerberg, E. W.; Roobol, M. J.; Kattan, M. W.; van der Kwast, T. H.; de Koning, H. J.; Schroder, F. H. Prediction of indolent prostate cancer: Validation and updating of a prognostic nomogram. J. Urol. 2007, 177, 107-112.
8. Ploussard, G.; Epstein, J. I.; Montironi, R.; Carroll, P. R.; Wirth, M.; Grimm, M. O.; Bjartell, A. S.; Montorsi, F.; Freedland, S. J.; Erbersdobler, A.; et al. The contemporary concept of significant versus insignificant prostate cancer. Eur. Urol. 2011, 60, 291-303.
9. Shariat, S. F.; Karakiewicz, P. I.; Roehrborn, C. G.; Kattan, M. W. An updated catalog of prostate cancer predictive tools. Cancer 2008, 113, 3075-3099.
10. Cooperberg, M. R.; Simko, J. P.; Cowan, J. E.; Reid, J. E.; Djalilvand, A.; Bhatnagar, S.; Gutin, A.; Lanchbury, J. S.; Swanson, G. P.; Stone, S.; et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J. Clin. Oncol. 2013, 31, 1428-1434.
11. Salami, S. S.; Schmidt, F.; Laxman, B.; Regan, M. M.; Rickman, D. S.; Scherr, D.; Bueti, G.; Siddiqui, J.; Tomlins, S. A.; Wei, J. T.; et al. Combining urinary detection of tmprss2: Erg and pca3 with serum psa to predict diagnosis of prostate cancer. Urol. Oncol. 2013, 31, 566-571.
12. Sartori, D. A.; Chan, D. W. Biomarkers in prostate cancer: What's new? Curr. Opin. Oncol. 2014, 26, 259-264.
13. Banez, L. L.; Sun, L.; van Leenders, G. J.; Wheeler, T. M.; Bangma, C. H.; Freedland, S. J.; Ittmann, M. M.; Lark, A. L.; Madden, J. F.; Hartman, A.; et al. Multicenter clinical validation of pitx2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. J. Urol. 2010, 184, 149-156.
14. Haldrup, C.; Mundbjerg, K.; Vestergaard, E. M.; Lamy, P.; Wild, P.; Schulz, W. A.; Arsov, C.; Visakorpi, T.; Borre, M.; Hoyer, S.; et al. DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer. J. Clin. Oncol. 2013, 31, 3250-3258.
15. Kristensen, H.; Haldrup, C.; Strand, S.; Mundbjerg, K.; Mortensen, M. M.; Thorsen, K.; Ostenfeld, M. S.; Wild, P. J.; Arsov, C.; Goering, W.; et al. Hypermethylation of the gabre~mir-452~mir-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy. Clin. Cancer Res. 2014, 20, 2169-2181.
16. Weiss, G.; Cottrell, S.; Distler, J.; Schatz, P.; Kristiansen, G.; Ittmann, M.; Haefliger, C.; Lesche, R.; Hartmann, A.; Corman, J.; et al. DNA methylation of the pitx2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy. J. Urol. 2009, 181, 1678-1685.
17. Li, E.; Bestor, T. H.; Jaenisch, R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 1992, 69, 915-926.
18. Wolffe, A. P.; Matzke, M. A. Epigenetics: Regulation through repression. Science 1999, 286, 481-486.
19. Jones, P. A. Functions of DNA methylation: Islands, start sites, gene bodies and beyond. Nat. Rev. 2012, 13, 484-492.
20. Baylin, S. B.; Jones, P. A. A decade of exploring the cancer epigenome-Biological and translational implications. Nat. Rev. 2011, 11, 726-734.
21. Dobosy, J. R.; Roberts, J. L.; Fu, V. X.; Jarrard, D. F. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J. Urol. 2007, 177, 822-831.
22. Baylin, S. B.; Esteller, M.; Rountree, M. R.; Bachman, K. E.; Schuebel, K.; Herman, J. G. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum. Mol. Genet. 2001, 10, 687-692.
23. Aryee, M. J.; Liu, W.; Engelmann, J. C.; Nuhn, P.; Gurel, M.; Haffner, M. C.; Esopi, D.; Irizarry, R. A.; Getzenberg, R. H.; Nelson, W. G.; et al. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci. Transl. Med. 2013, 5, doi: 10. 1126/scitranslmed. 3005211.
24. Nelson, W. G.; Yegnasubramanian, S.; Agoston, A. T.; Bastian, P. J.; Lee, B. H.; Nakayama, M.; De Marzo, A. M. Abnormal DNA methylation, epigenetics, and prostate cancer. Front. Biosci. 2007, 12, 4254-4266.
25. Issa, J. P. DNA methylation as a clinical marker in oncology. J. Clin. Oncol. 2012, 30, 2566-2568.
26. Li, L. C.; Carroll, P. R.; Dahiya, R. Epigenetic changes in prostate cancer: Implication for diagnosis and treatment. J. Nat. Cancer Inst. 2005, 97, 103-115.
27. Phe, V.; Cussenot, O.; Roupret, M. Methylated genes as potential biomarkers in prostate cancer. BJU Int. 2010, 105, 1364-1370.
28. Brocks, D.; Assenov, Y.; Minner, S.; Bogatyrova, O.; Simon, R.; Koop, C.; Oakes, C.; Zucknick, M.; Lipka, D. B.; Weischenfeldt, J.; et al. Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer. Cell Rep. 2014, 8, 798-806.
29. Herman, J. G.; Graff, J. R.; Myohanen, S.; Nelkin, B. D.; Baylin, S. B. Methylation-specific pcr: A novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA 1996, 93, 9821-9826.
30. Stewart, G. D.; van Neste, L.; Delvenne, P.; Delree, P.; Delga, A.; McNeill, S. A.; O'Donnell, M.; Clark, J.; van Criekinge, W.; Bigley, J.; et al. Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: Results of the matloc study. J. Urol. 2013, 189, 1110-1116.
31. Bastian, P. J.; Palapattu, G. S.; Lin, X.; Yegnasubramanian, S.; Mangold, L. A.; Trock, B.; Eisenberger, M. A.; Partin, A. W.; Nelson, W. G. Preoperative serum DNA gstp1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin. Cancer Res. 2005, 11, 4037-4043.
32. Ellinger, J.; Haan, K.; Heukamp, L. C.; Kahl, P.; Buttner, R.; Muller, S. C.; von Ruecker, A.; Bastian, P. J. CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate 2008, 68, 42-49.
33. Okegawa, T.; Nutahara, K.; Higashihara, E. Association of circulating tumor cells with tumor-related methylated DNA in patients with hormone-refractory prostate cancer. Int. J. Urol. 2010, 17, 466-475.
34. Payne, S. R.; Serth, J.; Schostak, M.; Kamradt, J.; Strauss, A.; Thelen, P.; Model, F.; Day, J. K.; Liebenberg, V.; Morotti, A.; et al. DNA methylation biomarkers of prostate cancer: Confirmation of candidates and evidence urine is the most sensitive body fluid for non-invasive detection. Prostate 2009, 69, 1257-1269.
35. Roupret, M.; Hupertan, V.; Catto, J. W.; Yates, D. R.; Rehman, I.; Proctor, L. M.; Phillips, J.; Meuth, M.; Cussenot, O.; Hamdy, F. C. Promoter hypermethylation in circulating blood cells identifies prostate cancer progression. Int. J. Cancer 2008, 122, 952-956.
36. Goessl, C.; Krause, H.; Muller, M.; Heicappell, R.; Schrader, M.; Sachsinger, J.; Miller, K. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res. 2000, 60, 5941-5945.
37. Chiam, K.; Ricciardelli, C.; Bianco-Miotto, T. Epigenetic biomarkers in prostate cancer: Current and future uses. Cancer Lett. 2014, 342, 248-256.
38. Goering, W.; Kloth, M.; Schulz, W. A. DNA methylation changes in prostate cancer. Method. Mol. Biol 2012, 863, 47-66.
39. Maier, S.; Nimmrich, I.; Koenig, T.; Eppenberger-Castori, S.; Bohlmann, I.; Paradiso, A.; Spyratos, F.; Thomssen, C.; Mueller, V.; Nahrig, J.; et al. DNA-methylation of the homeodomain transcription factor pitx2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients-Technical and clinical validation in a multi-centre setting in collaboration with the european organisation for research and treatment of cancer (eortc) pathobiology group. Eur. J. Cancer 2007, 43, 1679-1686.
40. Vinarskaja, A.; Schulz, W. A.; Ingenwerth, M.; Hader, C.; Arsov, C. Association of pitx2 mrna down-regulation in prostate cancer with promoter hypermethylation and poor prognosis. Urol. Oncol. 2013, 31, 622-627.
41. Schayek, H.; Bentov, I.; Jacob-Hirsch, J.; Yeung, C.; Khanna, C.; Helman, L. J.; Plymate, S. R.; Werner, H. Global methylation analysis identifies pitx2 as an upstream regulator of the androgen receptor and Igf-I receptor genes in prostate cancer. Horm. Metab. Res. 2012, 44, 511-519.
42. Anglim, P. P.; Galler, J. S.; Koss, M. N.; Hagen, J. A.; Turla, S.; Campan, M.; Weisenberger, D. J.; Laird, P. W.; Siegmund, K. D.; Laird-Offringa, I. A. Identification of a panel of sensitive and specific DNA methylation markers for squamous cell lung cancer. Mol. Cancer 2008, 7, 62.
43. Toyota, M.; Kopecky, K. J.; Toyota, M. O.; Jair, K. W.; Willman, C. L.; Issa, J. P. Methylation profiling in acute myeloid leukemia. Blood 2001, 97, 2823-2829.
44. Schatz, P.; Dietrich, D.; Koenig, T.; Burger, M.; Lukas, A.; Fuhrmann, I.; Kristiansen, G.; Stoehr, R.; Schuster, M.; Lesche, R.; et al. Development of a diagnostic microarray assay to assess the risk of recurrence of prostate cancer based on pitx2 DNA methylation. J. Mol. Diagn. 2010, 12, 345-353.
45. Dietrich, D.; Hasinger, O.; Banez, L. L.; Sun, L.; van Leenders, G. J.; Wheeler, T. M.; Bangma, C. H.; Wernert, N.; Perner, S.; Freedland, S. J.; et al. Development and clinical validation of a real-time pcr assay for pitx2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy. J. Mol. Diagn. 2013, 15, 270-279.
46. Aoki, K.; Taketo, M. M. Adenomatous polyposis coli (APC): A multi-functional tumor suppressor gene. J. Cell Sci. 2007, 120, 3327-3335.
47. Chen, Y.; Li, J.; Yu, X.; Li, S.; Zhang, X.; Mo, Z.; Hu, Y. APC gene hypermethylation and prostate cancer: A systematic review and meta-analysis. Eur. J. Hum. Genet. 2013, 21, 929-935.
48. Alumkal, J. J.; Zhang, Z.; Humphreys, E. B.; Bennett, C.; Mangold, L. A.; Carducci, M. A.; Partin, A. W.; Garrett-Mayer, E.; DeMarzo, A. M.; Herman, J. G. Effect of DNA methylation on identification of aggressive prostate cancer. Urology 2008, 72, 1234-1239.
49. Ellinger, J.; Bastian, P. J.; Jurgan, T.; Biermann, K.; Kahl, P.; Heukamp, L. C.; Wernert, N.; Muller, S. C.; von Ruecker, A. CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology 2008, 71, 161-167.
50. Henrique, R.; Ribeiro, F. R.; Fonseca, D.; Hoque, M. O.; Carvalho, A. L.; Costa, V. L.; Pinto, M.; Oliveira, J.; Teixeira, M. R.; Sidransky, D.; et al. High promoter methylation levels of apc predict poor prognosis in sextant biopsies from prostate cancer patients. Clin. Cancer Res. 2007, 13, 6122-6129.
51. Liu, L.; Kron, K. J.; Pethe, V. V.; Demetrashvili, N.; Nesbitt, M. E.; Trachtenberg, J.; Ozcelik, H.; Fleshner, N. E.; Briollais, L.; van der Kwast, T. H.; et al. Association of tissue promoter methylation levels of APC, TGFBETA2, HOXD3 and RASSF1A with prostate cancer progression. Int. J. Cancer 2011, 129, 2454-2462.
52. Moritz, R.; Ellinger, J.; Nuhn, P.; Haese, A.; Muller, S. C.; Graefen, M.; Schlomm, T.; Bastian, P. J. DNA hypermethylation as a predictor of PSA recurrence in patients with low-and intermediate-grade prostate cancer. Anticancer Res. 2013, 33, 5249-5254.
53. Richiardi, L.; Fiano, V.; Grasso, C.; Zugna, D.; Delsedime, L.; Gillio-Tos, A.; Merletti, F. Methylation of APC and GSTP1 in non-neoplastic tissue adjacent to prostate tumour and mortality from prostate cancer. PLoS One 2013, 8, e68162.
54. Richiardi, L.; Fiano, V.; Vizzini, L.; de Marco, L.; Delsedime, L.; Akre, O.; Tos, A. G.; Merletti, F. Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients. J. Clin. Oncol. 2009, 27, 3161-3168.
55. Rosenbaum, E.; Hoque, M. O.; Cohen, Y.; Zahurak, M.; Eisenberger, M. A.; Epstein, J. I.; Partin, A. W.; Sidransky, D. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin. Cancer Res. 2005, 11, 8321-8325.
56. Yegnasubramanian, S.; Kowalski, J.; Gonzalgo, M. L.; Zahurak, M.; Piantadosi, S.; Walsh, P. C.; Bova, G. S.; de Marzo, A. M.; Isaacs, W. B.; Nelson, W. G. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 2004, 64, 1975-1986.
57. Cottrell, S.; Jung, K.; Kristiansen, G.; Eltze, E.; Semjonow, A.; Ittmann, M.; Hartmann, A.; Stamey, T.; Haefliger, C.; Weiss, G. Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis. J. Urol. 2007, 177, 1753-1758.
58. Stott-Miller, M.; Zhao, S.; Wright, J. L.; Kolb, S.; Bibikova, M.; Klotzle, B.; Ostrander, E. A.; Fan, J. B.; Feng, Z.; Stanford, J. L. Validation study of genes with hypermethylated promoter regions associated with prostate cancer recurrence. Cancer Epidemiol. Biomark. Prev. 2014, 23, 1331-1339.
59. Woodson, K.; O'Reilly, K. J.; Ward, D. E.; Walter, J.; Hanson, J.; Walk, E. L.; Tangrea, J. A. CD44 and PTGS2 methylation are independent prognostic markers for biochemical recurrence among prostate cancer patients with clinically localized disease. Epigenetics 2006, 1, 183-186.
60. Kron, K. J.; Liu, L.; Pethe, V. V.; Demetrashvili, N.; Nesbitt, M. E.; Trachtenberg, J.; Ozcelik, H.; Fleshner, N. E.; Briollais, L.; van der Kwast, T. H.; et al. DNA methylation of HOXD3 as a marker of prostate cancer progression. Lab. Investig. 2010, 90, 1060-1067.
61. Kron, K.; Liu, L.; Trudel, D.; Pethe, V.; Trachtenberg, J.; Fleshner, N.; Bapat, B.; van der Kwast, T. Correlation of ERG expression and DNA methylation biomarkers with adverse clinicopathologic features of prostate cancer. Clin. Cancer Res. 2012, 18, 2896-2904.
62. Rizzo, M. T. Cyclooxygenase-2 in oncogenesis. Clin. Chim. Acta 2011, 412, 671-687.
63. Bastian, P. J.; Ellinger, J.; Wellmann, A.; Wernert, N.; Heukamp, L. C.; Muller, S. C.; von Ruecker, A. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin. Cancer Res. 2005, 11, 4097-4106.
64. Vasiljevic, N.; Wu, K.; Brentnall, A. R.; Kim, D. C.; Thorat, M. A.; Kudahetti, S. C.; Mao, X.; Xue, L.; Yu, Y.; Shaw, G. L.; et al. Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing. Dis. Markers 2011, 30, 151-161.
65. Moison, C.; Assemat, F.; Daunay, A.; Tost, J.; Guieysse-Peugeot, A. L.; Arimondo, P. B. Synergistic chromatin repression of the tumor suppressor gene rarb in human prostate cancers. Epigenetics 2014, 9, 477-482.
66. Hesson, L. B.; Cooper, W. N.; Latif, F. The role of rassf1a methylation in cancer. Dis. Markers 2007, 23, 73-87.
67. Kron, K.; Pethe, V.; Briollais, L.; Sadikovic, B.; Ozcelik, H.; Sunderji, A.; Venkateswaran, V.; Pinthus, J.; Fleshner, N.; van der Kwast, T.; et al. Discovery of novel hypermethylated genes in prostate cancer using genomic cpg island microarrays. PLoS One 2009, 4, e4830.
68. Oncomine Homepage. Avaible online: https://www. oncomine. org/resource/main. html, (accessed on 14 July 2014).
69. Van Neste, L.; Herman, J. G.; Otto, G.; Bigley, J. W.; Epstein, J. I.; Van Criekinge, W. The epigenetic promise for prostate cancer diagnosis. Prostate 2012, 72, 1248-1261.
70. Nakayama, M.; Gonzalgo, M. L.; Yegnasubramanian, S.; Lin, X.; De Marzo, A. M.; Nelson, W. G. Gstp1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J. Cell. Biochem. 2004, 91, 540-552.
71. Moura, C. M.; Pontes, J.; Reis, S. T.; Viana, N. I.; Morais, D. R.; Dip, N.; Katz, B.; Srougi, M.; Leite, K. R. Expression profile of standard and variants forms of CD44 related to prostate cancer behavior. Int. J. Biol. Markers 2014, 13, doi: 10. 5301/jbm. 5000091.
72. Hulf, T.; Sibbritt, T.; Wiklund, E. D.; Patterson, K.; Song, J. Z.; Stirzaker, C.; Qu, W.; Nair, S.; Horvath, L. G.; Armstrong, N. J.; et al. Epigenetic-induced repression of microrna-205 is associated with med1 activation and a poorer prognosis in localized prostate cancer. Oncogene 2013, 32, 2891-2899.
73. Olkhov-Mitsel, E.; Van der Kwast, T.; Kron, K. J.; Ozcelik, H.; Briollais, L.; Massey, C.; Recker, F.; Kwiatkowski, M.; Fleshner, N. E.; Diamandis, E. P., et al. Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer. Epigenetics 2012, 7, 1037-1045.
74. Mahapatra, S.; Klee, E. W.; Young, C. Y.; Sun, Z.; Jimenez, R. E.; Klee, G. G.; Tindall, D. J.; Donkena, K. V. Global methylation profiling for risk prediction of prostate cancer. Clin. Cancer Res. 2012, 18, 2882-2895.
75. Kim, J. W.; Kim, S. T.; Turner, A. R.; Young, T.; Smith, S.; Liu, W.; Lindberg, J.; Egevad, L.; Gronberg, H.; Isaacs, W. B.; et al. Identification of new differentially methylated genes that have potential functional consequences in prostate cancer. PLoS One 2012, 7, e48455.
76. Vasiljevic, N.; Ahmad, A. S.; Beesley, C.; Thorat, M. A.; Fisher, G.; Berney, D. M.; Moller, H.; Yu, Y.; Lu, Y. J.; Cuzick, J.; et al. Association between DNA methylation of hspb1 and death in low gleason score prostate cancer. Prostate Cancer Prostatic Dis. 2013, 16, 35-40.
77. Pierconti, F.; Martini, M.; Pinto, F.; Cenci, T.; Capodimonti, S.; Calarco, A.; Bassi, P. F.; Larocca, L. M. Epigenetic silencing of SOCS3 identifies a subset of prostate cancer with an aggressive behavior. Prostate 2011, 71, 318-325.
78. Lin, P. C.; Giannopoulou, E. G.; Park, K.; Mosquera, J. M.; Sboner, A.; Tewari, A. K.; Garraway, L. A.; Beltran, H.; Rubin, M. A.; Elemento, O. Epigenomic alterations in localized and advanced prostate cancer. Neoplasia 2013, 15, 373-383.
79. Chan, K. C.; Jiang, P.; Chan, C. W.; Sun, K.; Wong, J.; Hui, E. P.; Chan, S. L.; Chan, W. C.; Hui, D. S.; Ng, S. S.; et al. Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. Proc. Natl. Acad. Sci. USA 2013, 110, 18761-18768.
80. Wu, T.; Giovannucci, E.; Welge, J.; Mallick, P.; Tang, W. Y.; Ho, S. M. Measurement of gstp1 promoter methylation in body fluids may complement PSA screening: A meta-analysis. Br. J. Cancer 2011, 105, 65-73.
81. Prensner, J. R.; Rubin, M. A.; Wei, J. T.; Chinnaiyan, A. M. Beyond PSA: The next generation of prostate cancer biomarkers. Sci. Transl. Med. 2012, 4, 127rv123.
82. Schroder, F. H.; Hugosson, J.; Roobol, M. J.; Tammela, T. L.; Ciatto, S.; Nelen, V.; Kwiatkowski, M.; Lujan, M.; Lilja, H.; Zappa, M.; et al. Screening and prostate-cancer mortality in a randomized european study. N. Engl. J. Med. 2009, 360, 1320-1328.
83. Vestergaard, E. M.; Nexo, E.; Torring, N.; Borre, M.; Orntoft, T. F.; Sorensen, K. D. Promoter hypomethylation and upregulation of trefoil factors in prostate cancer. Int. J. Cancer 2010, 127, 1857-1865.
84. Sorensen, K. D.; Wild, P. J.; Mortezavi, A.; Adolf, K.; Torring, N.; Heeboll, S.; Ulhoi, B. P.; Ottosen, P.; Sulser, T.; Hermanns, T.; et al. Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy. Clin. Cancer Res. 2009, 15, 1400-1410.
85. Trock, B. J.; Brotzman, M. J.; Mangold, L. A.; Bigley, J. W.; Epstein, J. I.; McLeod, D.; Klein, E. A.; Jones, J. S.; Wang, S.; McAskill, T.; et al. Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies. BJU Int. 2012, 110, 56-62.
86. Truong, M.; Yang, B.; Livermore, A.; Wagner, J.; Weeratunga, P.; Huang, W.; Dhir, R.; Nelson, J.; Lin, D. W.; Jarrard, D. F. Using the epigenetic field defect to detect prostate cancer in biopsy negative patients. J. Urol. 2013, 189, 2335-2341.
87. Bastian, P. J.; Ellinger, J.; Heukamp, L. C.; Kahl, P.; Muller, S. C.; von Rucker, A. Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy. Eur. Urol. 2007, 51, 665-674.
88. Liu, J. W.; Nagpal, J. K.; Jeronimo, C.; Lee, J. E.; Henrique, R.; Kim, M. S.; Ostrow, K. L.; Yamashita, K.; van Criekinge, V.; Wu, G.; et al. Hypermethylation of MCAM gene is associated with advanced tumor stage in prostate cancer. Prostate 2008, 68, 418-426.
89. Donovan, M. J.; Cordon-Cardo, C. Genomic analysis in active surveillance: Predicting high-risk disease using tissue biomarkers. Curr. Opin. Urol. 2014, 24, 303-310.
90. Royston, P.; Altman, D. G.; Sauerbrei, W. Dichotomizing continuous predictors in multiple regression: A bad idea. Stat. Med. 2006, 25, 127-141.
91. Borno, S. T.; Fischer, A.; Kerick, M.; Falth, M.; Laible, M.; Brase, J. C.; Kuner, R.; Dahl, A.; Grimm, C.; Sayanjali, B.; et al. Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with mir-26a hypermethylation. Cancer Discov. 2012, 2, 1024-1035.
92. Kim, J. H.; Dhanasekaran, S. M.; Prensner, J. R.; Cao, X.; Robinson, D.; Kalyana-Sundaram, S.; Huang, C.; Shankar, S.; Jing, X.; Iyer, M.; et al. Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Res. 2011, 21, 1028-1041.
93. Kobayashi, Y.; Absher, D. M.; Gulzar, Z. G.; Young, S. R.; McKenney, J. K.; Peehl, D. M.; Brooks, J. D.; Myers, R. M.; Sherlock, G. DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res. 2011, 21, 1017-1027.
94. Rang, F. J.; Boonstra, J. Causes and consequences of age-related changes in DNA methylation: A role for ROS? Biology 2014, 3, 403-425.
95. Kwabi-Addo, B.; Chung, W.; Shen, L.; Ittmann, M.; Wheeler, T.; Jelinek, J.; Issa, J. P. Age-related DNA methylation changes in normal human prostate tissues. Clin. Cancer Res. 2007, 13, 3796-3802.
96. Lindberg, J.; Klevebring, D.; Liu, W.; Neiman, M.; Xu, J.; Wiklund, P.; Wiklund, F.; Mills, I. G.; Egevad, L.; Gronberg, H. Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins. Eur. Urol. 2013, 63, 347-353.
97. Gonzalez-Masia, J. A.; Garcia-Olmo, D.; Garcia-Olmo, D. C. Circulating nucleic acids in plasma and serum (CNAPS): Applications in oncology. Oncol. Targets Ther. 2013, 6, 819-832.
98. Gormally, E.; Caboux, E.; Vineis, P.; Hainaut, P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: Practical aspects and biological significance. Mutat. Res. 2007, 635, 105-117.
99. Devonshire, A. S.; Whale, A. S.; Gutteridge, A.; Jones, G.; Cowen, S.; Foy, C. A.; Huggett, J. F. Towards standardisation of cell-free DNA measurement in plasma: Controls for extraction efficiency, fragment size bias and quantification. Anal. Bioanal. Chem. 2014, doi: 10. 1007/s00216-014-7835-3.
100. Ralla, B.; Stephan, C.; Meller, S.; Dietrich, D.; Kristiansen, G.; Jung, K. Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies. Crit. Rev. Clin. Lab. Sci. 2014, 51, 200-231.
101. Lo, Y. M.; Zhang, J.; Leung, T. N.; Lau, T. K.; Chang, A. M.; Hjelm, N. M. Rapid clearance of fetal DNA from maternal plasma. Am. J. Hum. Genet. 1999, 64, 218-224.
102. Narayanan, S.; Appleton, H. D. Creatinine: A review. Clin. Chem. 1980, 26, 1119-1126.
103. Yu, Y. P.; Ding, Y.; Chen, R.; Liao, S. G.; Ren, B. G.; Michalopoulos, A.; Michalopoulos, G.; Nelson, J.; Tseng, G. C.; Luo, J. H. Whole-genome methylation sequencing reveals distinct impact of differential methylations on gene transcription in prostate cancer. Am. J. Pathol. 2013, 183, 1960-1970.
104. Timp, W.; Feinberg, A. P. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat. Rev. 2013, 13, 497-510.
105. Stadler, M. B.; Murr, R.; Burger, L.; Ivanek, R.; Lienert, F.; Scholer, A.; van Nimwegen, E.; Wirbelauer, C.; Oakeley, E. J.; Gaidatzis, D.; et al. DNA-binding factors shape the mouse methylome at distal regulatory regions. Nature 2011, 480, 490-495.
106. Ziller, M. J.; Gu, H.; Muller, F.; Donaghey, J.; Tsai, L. T.; Kohlbacher, O.; de Jager, P. L.; Rosen, E. D.; Bennett, D. A.; Bernstein, B. E.; et al. Charting a dynamic DNA methylation landscape of the human genome. Nature 2013, 500, 477-481.
107. Hon, G. C.; Rajagopal, N.; Shen, Y.; McCleary, D. F.; Yue, F.; Dang, M. D.; Ren, B. Epigenetic memory at embryonic enhancers identified in DNA methylation maps from adult mouse tissues. Nat. Egenet. 2013, 45, 1198-1206.
108. Xie, W.; Schultz, M. D.; Lister, R.; Hou, Z.; Rajagopal, N.; Ray, P.; Whitaker, J. W.; Tian, S.; Hawkins, R. D.; Leung, D.; et al. Epigenomic analysis of multilineage differentiation of human embryonic stem cells. Cell 2013, 153, 1134-1148.
109. Jeong, M.; Sun, D.; Luo, M.; Huang, Y.; Challen, G. A.; Rodriguez, B.; Zhang, X.; Chavez, L.; Wang, H.; Hannah, R.; et al. Large conserved domains of low DNA methylation maintained by dnmt3a. Nat. Genet. 2014, 46, 17-23.
110. Hnisz, D.; Abraham, B. J.; Lee, T. I.; Lau, A.; Saint-Andre, V.; Sigova, A. A.; Hoke, H. A.; Young, R. A. Super-enhancers in the control of cell identity and disease. Cell 2013, 155, 934-947.
111. Loven, J.; Hoke, H. A.; Lin, C. Y.; Lau, A.; Orlando, D. A.; Vakoc, C. R.; Bradner, J. E.; Lee, T. I.; Young, R. A. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013, 153, 320-334.
112. Aran, D.; Sabato, S.; Hellman, A. DNA methylation of distal regulatory sites characterizes dysregulation of cancer genes. Genome Biol. 2013, 14, R21.
113. Aran, D.; Hellman, A. Unmasking risk loci: DNA methylation illuminates the biology of cancer predisposition: Analyzing DNA methylation of transcriptional enhancers reveals missed regulatory links between cancer risk loci and genes. BioEssays 2014, 36, 184-190.
114. Jones, P. A. At the tipping point for epigenetic therapies in cancer. J. Clin. Investig. 2014, 124, 14-16.